NasdaqCM:QTTBBiotechs
Q32 Bio (QTTB) One Off Driven Q4 Profit Challenges Earnings Decline Narrative
Q32 Bio (QTTB) has just posted its FY 2025 numbers, reporting fourth quarter revenue of US$53.7 million and basic EPS of US$4.60, alongside trailing 12 month basic EPS of US$2.42 and net income of US$29.8 million. The company’s quarterly revenue has moved from US$0 and a basic EPS loss of US$1.16 in Q4 2024 to US$53.7 million and US$4.60 in Q4 2025. Interim 2025 quarters showed no revenue and basic EPS losses between US$0.60 and US$0.90, so investors will likely focus on how durable these...